Pentobarbital sodium saltEnhances GABAergic activity CAS# 57-33-0 |
- Pentamidine
Catalog No.:BCC3836
CAS No.:100-33-4
- Pentamidine dihydrochloride
Catalog No.:BCC5194
CAS No.:50357-45-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 57-33-0 | SDF | Download SDF |
PubChem ID | 23676152 | Appearance | Powder |
Formula | C11H17N2NaO3 | M.Wt | 248.25 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H, | ||
SMILES | CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+] | ||
Standard InChIKey | QGMRQYFBGABWDR-UHFFFAOYSA-M | ||
Standard InChI | InChI=1S/C11H18N2O3.Na/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Enhances GABAergic activity. Short-acting barbiturate; long-acting barbiturate also available. |
Pentobarbital sodium salt Dilution Calculator
Pentobarbital sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.0282 mL | 20.141 mL | 40.282 mL | 80.5639 mL | 100.7049 mL |
5 mM | 0.8056 mL | 4.0282 mL | 8.0564 mL | 16.1128 mL | 20.141 mL |
10 mM | 0.4028 mL | 2.0141 mL | 4.0282 mL | 8.0564 mL | 10.0705 mL |
50 mM | 0.0806 mL | 0.4028 mL | 0.8056 mL | 1.6113 mL | 2.0141 mL |
100 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 0.8056 mL | 1.007 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Phenobarbital sodium salt
Catalog No.:BCC6230
CAS No.:57-30-7
- Strychnine
Catalog No.:BCN4978
CAS No.:57-24-9
- Vincristine
Catalog No.:BCN5411
CAS No.:57-22-7
- Urea
Catalog No.:BCC8034
CAS No.:57-13-6
- Stearic Acid
Catalog No.:BCN3820
CAS No.:57-11-4
- Palmitic acid
Catalog No.:BCN1206
CAS No.:57-10-3
- Flupirtine
Catalog No.:BCC4282
CAS No.:56995-20-1
- NSC 87877
Catalog No.:BCC2468
CAS No.:56990-57-9
- U 46619
Catalog No.:BCC7207
CAS No.:56985-40-1
- Boc-Cys(tBu)-OH
Catalog No.:BCC3379
CAS No.:56976-06-8
- Gabexate mesylate
Catalog No.:BCC2096
CAS No.:56974-61-9
- 9,9'-Di-O-(E)-feruloylsecoisolariciresinol
Catalog No.:BCN1415
CAS No.:56973-66-1
- Benactyzine hydrochloride
Catalog No.:BCC8841
CAS No.:57-37-4
- Phenytoin
Catalog No.:BCC5070
CAS No.:57-41-0
- Esromiotin
Catalog No.:BCC8325
CAS No.:57-47-6
- Fructose
Catalog No.:BCN4969
CAS No.:57-48-7
- Sucrose
Catalog No.:BCN5780
CAS No.:57-50-1
- Chlorotetracycline
Catalog No.:BCC8913
CAS No.:57-62-5
- Ethinyl Estradiol
Catalog No.:BCC3777
CAS No.:57-63-6
- Probenecid
Catalog No.:BCC4832
CAS No.:57-66-9
- Sulfaguanidine
Catalog No.:BCC4727
CAS No.:57-67-0
- Sulfamethazine
Catalog No.:BCC4942
CAS No.:57-68-1
- Progesterone
Catalog No.:BCN2198
CAS No.:57-83-0
- Testosterone propionate
Catalog No.:BCC9172
CAS No.:57-85-2
Modulation of GABA(A) receptor channel gating by pentobarbital.[Pubmed:11744750]
J Physiol. 2001 Dec 15;537(Pt 3):715-33.
1. We have studied the kinetic properties of channel gating of recombinant alpha 1 beta 2 gamma 2L GABA(A) receptors transiently expressed in human embryonic kidney 293 cells, using the cell-attached, single-channel patch-clamp technique. The receptors were activated by GABA, beta-alanine or piperidine-4-sulfonic acid (P4S), and the effects of pentobarbital (PB) on single-channel activity were examined. 2. At relatively high concentrations of agonist, single-channel activity occurred in well-defined clusters. In global terms, PB increased the mean open time for events in clusters, without changing the mean closed time. The addition of PB shifted the curve relating the probability of being open in a cluster (P(o)) to lower agonist concentrations, and that shift could be accounted for by the changes in mean open time. 3. The intracluster closed-time histograms contained four components. The durations and relative frequencies of these closed-dwell components were not affected by the presence of 40 microM PB, at any agonist concentration. The duration of one component was dependent upon the concentration of agonist used to activate the receptor. Accordingly, the inverse of the mean duration of this component will be called the effective opening rate. 4. The channel-opening rate constant (beta) was determined from the value of the effective opening rate at a saturating agonist concentration. beta was about 1900 s(-1) when the receptors were activated by GABA, 1500 s(-1) when activated by beta-alanine, and too low to be determined when P4S was administered. In the presence of 40 microM PB, beta was about 1500 s(-1) when the receptors were activated by GABA, 1400 s(-1) when activated by beta-alanine, and 50 s(-1) when activated by P4S. Hence, the potentiating effect of PB is not mediated by a change in beta. The concentration of agonist producing a half-maximal effective opening rate also remained unaffected in the presence of PB, indicating that receptor affinity for agonists is not influenced by PB. 5. The distributions of the intracluster open durations elicited by GABA could be described by the sum of three exponentials, with mean durations of about 0.4, 2.4 and 6.3 ms. The duration and relative frequency of the components did not change with GABA concentration (20 microM to 1 mM). In the presence of 40 microM PB, however, the mean duration of the longest of the open times increased (mean durations of about 0.4, 2.0 and 13 ms). The intracluster open durations elicited by beta-alanine could be described by the sum of two exponential components (1.1 and 3.5 ms). However, in the presence of 40 microM PB the open-time distribution contained three exponential components (0.2, 2 and 10 ms). Finally, openings elicited by P4S exhibited two components (0.3 and 0.9 ms). In the presence of 40 microM PB, three components could be distinguished (0.5, 2.5 and 13 ms). 6. These observations indicate that the potentiating effect of PB on GABA type A (GABA(A)) receptors reflects effects on the open state(s) of the receptors. In the case of receptors activated by GABA, the observations are consistent with the idea that the action is the result of PB stabilizing one of the open states. The actions on receptors activated by P4S or beta-alanine are also broadly consistent with this idea. However, the changes in open-time distributions caused by PB appear to be more complex. Possible explanations of the effects of PB on gating by different agonists are considered.